

**CENTER FOR DRUG EVALUATION AND  
RESEARCH**

*APPLICATION NUMBER:*  
**NDA 22-253 & 22-254**

**STATISTICAL REVIEW(S)**



U.S. Department of Health and Human Services  
Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Pharmacoepidemiology and Statistical Science  
Office of Biostatistics

## STATISTICAL REVIEW AND EVALUATION CLINICAL STUDIES

**NDA/Serial Number:** 22,253

**Drug Name:** Lacosamide

**Indication(s):** Adjunctive Therapy for Partial Seizures

**Applicant:** Schwarz

**Submission Date:** Sept, 28 2007

**Review Priority:** Standard

**Biometrics Division:** Division of Biometrics I

**Statistical Reviewer:** Tristan Massie, Ph.D.

**Concurring Reviewers:** Kun Jin, Ph.D., Team Leader

Kooros Mahjoob, Ph.D., Deputy Division Director

**Medical Division:** Neurology

**Clinical Team:** Norman Hershkowitz, M.D., Ph.D., Acting Team Leader

Russell Katz, M.D., Division Director

**Project Manager:** Jacqueline Ware

**Keywords:** log transformation, analysis of covariance, drop-outs, dose-response, multiple comparisons

# Table of Contents

LIST OF TABLES.....	4
LIST OF FIGURES.....	4
<b>1 EXECUTIVE SUMMARY .....</b>	<b>5</b>
1.1 CONCLUSIONS AND RECOMMENDATIONS .....	5
1.2 BRIEF OVERVIEW OF CLINICAL STUDIES .....	5
1.3 STATISTICAL ISSUES AND FINDINGS .....	6
<b>2 INTRODUCTION .....</b>	<b>7</b>
2.1 OVERVIEW.....	7
2.2 DATA SOURCES .....	8
<b>3 STATISTICAL EVALUATION .....</b>	<b>8</b>
3.1 EVALUATION OF EFFICACY .....	8
3.1.1 <i>Study 667</i> .....	8
3.1.1.1 Objectives .....	8
3.1.1.2 Study design.....	8
3.1.1.3 Statistical Analysis Plan.....	10
3.1.1.4 Patient Disposition .....	13
3.1.1.5 Baseline Demographics.....	16
3.1.1.6 Sponsor's Results .....	17
3.1.1.7 Reviewer's Results.....	22
3.1.1.8 Secondary Analyses.....	26
3.1.2 <i>Study 754</i> .....	26
3.1.2.1 Study Design and Statistical Analysis Plan.....	26
3.1.2.2 Patient Disposition .....	29
3.1.2.3 Baseline Demographics and Disease Characteristics .....	30
3.1.2.4 Sponsor's Results.....	31
3.1.2.5 Reviewer's Results.....	32
3.1.2.6 Secondary Analyses .....	35
3.1.3 <i>Study 755</i> .....	36
3.1.3.1 Objectives .....	36
3.1.3.2 Study Design.....	36
3.1.3.3 Statistical Analysis Plan.....	37
3.1.3.4 Patient Disposition .....	42
3.1.3.5 Baseline Demographics.....	43
3.1.3.6 Sponsor's Results .....	45
3.1.3.7 Reviewer's Results.....	48
3.1.3.8 Secondary Analyses .....	50
3.2 EVALUATION OF SAFETY.....	51
<b>4 FINDINGS IN SPECIAL/SUBGROUP POPULATIONS .....</b>	<b>51</b>
4.1 GENDER, RACE AND AGE .....	51
4.1.1 <i>Gender</i> .....	51
4.1.2 <i>Race</i> .....	53
4.1.3 <i>Age</i> .....	54
4.2 OTHER SPECIAL/SUBGROUP POPULATIONS .....	54
4.2.1 <i>Individual Sites and Countries</i> .....	54
4.2.1.1 Study 667.....	54
4.2.1.2 Study 754.....	55
4.2.1.3 Study 755.....	56
<b>5 SUMMARY AND CONCLUSIONS .....</b>	<b>57</b>

5.1 STATISTICAL ISSUES AND COLLECTIVE EVIDENCE .....57  
5.2 CONCLUSIONS AND RECOMMENDATIONS .....58

*Appears This Way  
On Original*

## LIST OF TABLES

Table 1 Study 667: Schedule of Trial Procedures .....	10
Table 2 Study 667 Patient Disposition .....	15
Table 3 Study 667 Baseline Demographic and Disease Characteristics .....	16
Table 4 Study 667: Median Seizure frequency from Baseline to Maintenance Phase (FAS).....	17
Table 5 Study 667: Statistical Analysis for Percent Reduction of Seizure Frequency over Placebo at Maintenance Endpoint Population: Full Analysis Set.....	17
Table 6 Study 667: Statistical Analysis for $\geq 50\%$ Responder at Maintenance Endpoint .....	18
Table 7 Study 667: Response to Treatment from Baseline to Maintenance By Gender (Full Analysis Set).....	19
Table 8 Study 667: Responders to Treatment from Baseline to Maintenance By Region (Full Analysis Set).....	20
Table 9 Study 667: Reviewer's Results for Primary Analysis of Seizure Frequency over Maintenance Period.....	22
Table 10 Study 667: Assessment of the Impact of Dropouts on Primary Analysis .....	25
Table 11 Study 754: Patient Disposition (Safety Set) .....	29
Table 12 Study 754 Baseline Demographics and Disease Characteristics .....	30
Table 13 Study 754: Median seizure frequency per 28 days by treatment (Full Analysis Set) .....	31
Table 14 Study 754: Statistical analysis for percent reduction of seizure frequency over placebo for the Maintenance Phase (Full Analysis Set).....	32
Table 15 Study 754: Statistical analysis of $\geq 50\%$ reduction in seizure frequency for Maintenance Phase (FAS) .....	32
Table 16 Study 754: Primary Analysis Result.....	33
Table 17 Study 754: Sensitivity Analyses for the Assessment of the Impact of Missing Data/Dropouts .....	35
Table 18 Study 755: Schedule of Trial Procedures - All subjects .....	39
Table 19 Study 755 Disposition (Full Analysis Set) .....	43
Table 20 Study 755: Baseline Demographics and Disease Characteristics .....	44
Table 21 Study 755: Median seizure frequency per 28 days by treatment Population: FAS.....	46
Table 22 Study 755: Statistical analysis for percent reduction of seizure frequency over placebo for the Maintenance Phase Population: Full Analysis Set .....	46
Table 23 Study 755: Statistical analysis of 50% responder rates for the Maintenance Phase .....	47
Table 24 Study 755: Primary Analysis Result of Double Blind Seizure Frequency During Maintenance (FAS).....	48
Table 25 Study 755: Sensitivity Analyses for the Assessment of Missing Data/Dropout Impact .....	50
Table 26 Treatment Effect by Gender in Pooled FAS Population (inc. 667,754,755) .....	53
Table 27 Pooled Analysis of Double Blind Seizure Rate .....	58

## LIST OF FIGURES

Figure 1 Study 667: Median Percent Reduction of Seizure Frequency from Baseline to Maintenance Endpoint Population: Full Analysis Set .....	18
Figure 2 Study 667: Variation of Treatment Group LSMeans by Region .....	21
Figure 3 Study 755: Median percent reduction of seizure frequency from Baseline to Maintenance Phase Population: Full Analysis Set.....	47
Figure 4 Study 667: Assessment of Consistency of Treatment Effects by Gender .....	52
Figure 5 Study 667: Treatment Effects by Site (Excluding 200 mg group) .....	55
Figure 6 Study 754: Treatment Effects by Site.....	56
Figure 7 Study 755: Treatment Effects by Site.....	57

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.